These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 23073054)

  • 1. Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
    Leonard JP
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):540-2. PubMed ID: 23073054
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A treatment for activated B-cell-like DLBCL?
    Zinzani PL
    Lancet Oncol; 2014 Aug; 15(9):916-7. PubMed ID: 25042201
    [No Abstract]   [Full Text] [Related]  

  • 6. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in indolent lymphomas.
    Sousou T; Friedberg J
    Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody therapy for non-Hodgkin's lymphoma.
    Ansell SM
    Curr Opin Mol Ther; 2004 Apr; 6(2):175-81. PubMed ID: 15195930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
    Shaw T; Quan J; Totoritis MC
    Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
    [No Abstract]   [Full Text] [Related]  

  • 10. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
    Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
    Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Advances in the research of anti-CD20 therapeutic monoclonal antibodies].
    Deng CL; Zou J; Song HF
    Yao Xue Xue Bao; 2013 Oct; 48(10):1515-20. PubMed ID: 24417077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent progress in rituximab therapy and its resistance--how do we overcome?].
    Hatake K; Yokoyama M; Terui Y
    Gan To Kagaku Ryoho; 2007 Aug; 34(8):1177-82. PubMed ID: 17687198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.
    Cruz RI; Hernandez-Ilizaliturri FJ; Olejniczak S; Deeb G; Knight J; Wallace P; Thurberg BL; Kennedy W; Czuczman MS
    Leuk Lymphoma; 2007 Dec; 48(12):2424-36. PubMed ID: 18067019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
    Jourdan E; Richard B
    Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical applications of anti-CD20 antibodies.
    Gopal AK; Press OW
    J Lab Clin Med; 1999 Nov; 134(5):445-50. PubMed ID: 10560936
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.
    Sacchi S; Federico M; Dastoli G; Fiorani C; Vinci G; Clò V; Casolari B
    Crit Rev Oncol Hematol; 2001 Jan; 37(1):13-25. PubMed ID: 11164715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.